Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulia Francesca Manfredi
Observed names:
G Manfredi,
G. F Manfredi,
G.F. Manfredi,
Giulia F Manfredi,
Giulia F. Manfredi,
Giulia Francesca,
Giulia Manfredi
show all 7
Institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Hammersmith Hospital,
Azienda Ospedaliero Universitaria Maggiore della Carita,
Imperial College London
Observed institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
University of Pavia,
Hammersmith Hospital,
Victor Babeș University of Medicine and Pharmacy Timișoara,
Azienda Ospedaliero Universitaria Maggiore della Carita,
Imperial College London
show all 6
ORCID:
0000-0002-2399-5376
Observed ORCID:
0000-0002-2399-5376
OpenAlex ID:
A5066177947
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients
2020
·
Mattia Bellan
, Giuseppe Patti
, et al.
·
Scientific Reports
·
156
PDF
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
2024
·
Antonio D'Alessio
, Bernardo Stefanini
, et al.
·
The Lancet Oncology
·
109
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
2023
·
Ciro Celsa
, Giuseppe Cabibbo
, et al.
·
Journal of Hepatology
·
88
PDF
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
2024
·
Ciro Celsa
, Giuseppe Cabibbo
, et al.
·
Hepatology
·
85
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
2024
·
Claudia Angela Maria Fulgenzi
, Bernhard Scheiner
, et al.
·
JAMA Oncology
·
49
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
2024
·
Giuseppe Cabibbo
, Ciro Celsa
, et al.
·
Clinical Cancer Research
·
46
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19
2021
·
Enrico Guido Spinoni
, Marco Mennuni
, et al.
·
Circulation Arrhythmia and Electrophysiology
·
44
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19
2021
·
Mattia Bellan
, Danila Azzolina
, et al.
·
Disease Markers
·
43
PDF
High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module
2022
·
Cristina Rigamonti
, Micol Giulia Cittone
, et al.
·
Hepatology Communications
·
36
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
2023
·
Giulia Francesca Manfredi
, Ciro Celsa
, et al.
·
Journal of Hepatocellular Carcinoma
·
32
PDF
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
2024
·
Meng Wu
, Claudia A.M. Fulgenzi
, et al.
·
JHEP Reports
·
30
PDF
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
2023
·
Antonella Cammarota
, Valentina Zanuso
, et al.
·
Therapeutic Advances in Medical Oncology
·
22
PDF
Spleen stiffness measurement predicts decompensation and rules out high-risk oesophageal varices in primary biliary cholangitis
2023
·
Cristina Rigamonti
, Micol Giulia Cittone
, et al.
·
JHEP Reports
·
20
PDF
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort
2022
·
Erika Zecca
, Manuela Rizzi
, et al.
·
Viruses
·
20
PDF
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
2025
·
Pasquale Lombardi
, Jung Sun Kim
, et al.
·
JHEP Reports
·
18
PDF
Vitamin D in Systemic Sclerosis: A Review
2022
·
Mattia Perazzi
, Enrico Gallina
, et al.
·
Nutrients
·
18
PDF
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
2025
·
Ciro Celsa
, Gabriele Di Maria
, et al.
·
JAMA Oncology
·
14
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
2025
·
Giulia Francesca Manfredi
, Claudia Angela Maria Fulgenzi
, et al.
·
JHEP Reports
·
14
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
2025
·
Francesca Terracciani
, Antonio De Vincentis
, et al.
·
JHEP Reports
·
13
PDF
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
2024
·
Antonio De Vincentis
, Javier Ampuero
, et al.
·
Clinical Gastroenterology and Hepatology
·
13
PDF
Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study
2022
·
Mattia Bellan
, Lorenza Scotti
, et al.
·
Journal of Clinical Medicine
·
13
PDF
OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2024
·
Ciro Celsa
, Giuseppe Cabibbo
, et al.
·
Journal of Hepatology
·
12
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms
2021
·
Riccardo Moia
, Micol Giulia Cittone
, et al.
·
Frontiers in Oncology
·
12
PDF
Non-Celiac Gluten Sensitivity in patients with severe abdominal pain and bloating: The accuracy of ALCAT 5
2018
·
Michele Di Stefano
, Eugenia Vittoria Pesatori
, et al.
·
Clinical Nutrition ESPEN
·
12
Impact of Age and Sex on Viral Load in Hepatitis C Virus Infection
2024
·
Andrea Magri
, Giulia Francesca Manfredi
, et al.
·
Viruses
·
11
PDF
Show more works
View as search
Works count:
101
Citation count:
1,032
H-index:
16
I10-index:
26
Year
Topic
Type